SAN DIEGO, Dec. 23, 2016 /PRNewswire/ -- Johnson & Weaver, LLP announces that a class action complaint was filed on behalf of purchasers of Alexion Pharmaceuticals, Inc., (NASDAQ: ALXN) securities during the period between February 10, 2014 and November 9, 2016 (the "Class Period"). Alexion is a biopharmaceutical company that develops and commercializes therapeutic products. The lawsuit will seek to recover damages for shareholders.
According to the complaint, throughout the Class Period defendants issued materially false and misleading statements to investors and failed to disclose that: Alexion employed improper sales practices with respect to Soliris; as a result, Alexion's revenues from Soliris sales were unlikely to be sustainable; and therefore, Alexion's public statements were materially false and misleading at all relevant times.
If you have any questions concerning this notice, or if you purchased stock before the February 10, 2014, class period, please contact lead analyst Jim Baker (firstname.lastname@example.org) at 619-814-4471. If you email, please include your phone number.
Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain an absent class member.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/alexion-alxn-alert-johnson--weaver-llp-announces-filing-of-class-action-complaint-against-alexion-pharmaceuticals-inc-encourages-all-investors-to-contact-the-firm-for-information-300383477.html
SOURCE Johnson & Weaver, LLP